Battle of the milky way: Lymphatic targeted drug delivery for pathogen eradication
Journal of Controlled Release · 2023
DOI: 10.1016/j.jconrel.2023.10.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2023. Verfasst von Ali Taheri und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia. Hauptthemen laut MEDLINE: Lymphatic Vessels, Prodrugs. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Many viruses, bacteria, and parasites rely on the lymphatic system for survival, replication, and dissemination. While conventional anti-infectives can combat infection-causing agents in the bloodstream, they do not reach the lymphatic system to eradicate the pathogens harboured there. This can result in ineffective drug exposure and reduce treatment effectiveness. By developing effective lymphatic delivery strategies for antiviral, antibacterial, and antiparasitic drugs, their systemic pharmacokinetics may be improved, as would their ability to reach their target pathogens within the lymphatics, thereby improving clinical outcomes in a variety of acute and chronic infections with lymphatic involvement (e.g., acquired immunodeficiency syndrome, tuberculosis, and filariasis). Here, we discuss approaches to targeting anti-infective drugs to the intestinal and dermal lymphatics, aiming to eliminate pathogen reservoirs and interfere with their survival and reproduction inside the lymphatic system. These include optimized lipophilic prodrugs and drug delivery systems that promote lymphatic transport after oral and dermal drug intake. For intestinal lymphatic delivery via the chylomicron pathway, molecules should have logP values >5 and long-chain triglyceride solubilities >50 mg/g, and for dermal lymphatic delivery via interstitial lymphatic drainage, nanoparticle formulations with particle size between 10 and 100 nm are generally preferred. Insight from this review may promote new and improved therapeutic solutions for pathogen eradication and combating infective diseases, as lymphatic system involvement in pathogen dissemination and drug resistance has been neglected compared to other pathways leading to treatment failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.
- Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia. Electronic address: clive.prestidge@unisa.edu.au.
Zitieren
APA
Taheri, A., Bremmell, K. E., Joyce, P., & Prestidge, C. A. (2023). Battle of the milky way: Lymphatic targeted drug delivery for pathogen eradication. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2023.10.002
Vancouver
Taheri A, Bremmell KE, Joyce P, Prestidge CA. Battle of the milky way: Lymphatic targeted drug delivery for pathogen eradication. Journal of Controlled Release. 2023. doi:10.1016/j.jconrel.2023.10.002
BibTeX
@article{Taheri2023,
author = {Taheri, Ali and Bremmell, Kristen E and Joyce, Paul and Prestidge, Clive A},
title = {Battle of the milky way: Lymphatic targeted drug delivery for pathogen eradication},
journal = {Journal of Controlled Release},
year = {2023},
doi = {10.1016/j.jconrel.2023.10.002}
}
EUVIMED